期刊论文详细信息
Reviews in Urology
Management of Clinically Localized Prostate Cancer
Herbert Lepor1 
[1] Department of Urology, New York University School of Medicine, New York, NY
关键词: Prostate cancer;    Prostate-specific antigen;    Gleason score;    Radical prostatectomy;   
DOI  :  
学科分类:基础医学
来源: MedReviews, LLC
PDF
【 摘 要 】

Critics of screening have stated that early detection of prostate cancer does not necessarily reflect a diminishing death rate from the disease. However, several recent reports have demonstrated that the death rate from prostate cancer is decreasing, representing the most compelling validation for aggressive screening. Prostate cancer can be halted only if there is no evidence of systemic or regional metastases and the disease is confined to the surgical field or the radiation template. Surgeons and radiation oncologists must make a concerted effort to exclude men with regional and systemic metastases who are unlikely to benefit from treatment. With the widespread acceptance of prostate-specific antigen screening, a greater proportion of men are being diagnosed with clinically localized prostate cancer. Both radical prostatectomy and radiation therapy are able to halt disease spread in this significant subset of men, but survival outcomes indicate that radical prostatectomy is a more reliable treatment than radiation therapy for clinically localized prostate cancer. Overall, the immediate treatment-related morbidity of radical prostatectomy and radiation therapy in the modern era is quite low. Radical prostatectomy and radiation therapy appear to have a similar impact on continence and erectile function. There is a need for neoadjuvant and adjuvant therapies that can be utilized in those cases where radical prostatectomy and radiation are less likely to completely eradicate or destroy the cancer.

【 授权许可】

Unknown   

【 预 览 】
附件列表
Files Size Format View
RO201912040560021ZK.pdf 327KB PDF download
  文献评价指标  
  下载次数:12次 浏览次数:14次